Summary of COVID-19 glenzocimab studies

1. Pottecher et al., Targeting GPVI with glenzocimab in COVID-19 patients: Results from a randomized clinical trial

62 patient glenzocimab early treatment RCT: 60% higher progression (p=0.28) and 49% worse recovery (p=0.53).
RCT 61 hospitalized COVID-19 patients showing no significant difference in primary outcomes with glenzocimab (an anti-GPVI antibody) vs. placebo. Authors report glenzocimab showed a significant improvement in the NEWS-2 category at day 4, however the actual results are not provided. There were no deaths and no significant safety signals in either group. The results suggest targeting GPVI at this stage of disease severity may not be sufficient to prevent progression to ARDS.
Jun 2024, PLOS ONE, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0302897, https://c19p.org/pottecher